Though some authors conclude that the low rate of HER2 gene amplification in CCA does not justify HER2 testing, in the authors’ eyes the existing data provides sufficient evidence for the launch of first multi-center studies to evaluate clinical efficacy of targeted HER2 therapy. Here, ERBB2 is linked to cholangiocarcinoma.